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Abstract
Introduction Several studies have shown the usefulness of
positron emission tomography (PET) quantification using
standardised uptake values (SUV) for diagnosis and staging,
prognosis and response monitoring. Many factors affect SUV,
such as patient preparation procedures, scan acquisition, image
reconstruction and data analysis settings, and the variability in
methodology across centres prohibits exchange of SUV data.
Therefore, standardisation of 2-[18F] fluoro-2-deoxy-D-glucose
(FDG) PETwhole body procedures is required in multi-centre
trials.
Methods A protocol for standardisation of quantitative FDG
whole body PET studies in the Netherlands (NL) was defined.
This protocol is based on standardisation of: (1) patient
preparation; (2) matching of scan statistics by prescribing
dosage as function of patient weight, scan time per bed posi-
tion, percentage of bed overlap and image acquisition mode
(2D or 3D); (3) matching of image resolution by prescribing
reconstruction settings for each type of scanner; (4) matching
of data analysis procedure by defining volume of interest
methods and SUV calculations and; (5) finally, a multi-centre
QC procedure is defined using a 20-cm diameter phantom for
verification of scanner calibration and the NEMA NU 2 2001
Image Quality phantom for verification of activity concentra-
tion recoveries (i.e., verification of image resolution and
reconstruction convergence).
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Discussion This paper describes a protocol for standardi-
zation of quantitative FDG whole body multi-centre PET
studies.
Conclusion The protocol was successfully implemented in
the Netherlands and has been approved by the Netherlands
Society of Nuclear Medicine.
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Quantification of FDG whole body PET studies
and need for standardisation of FDG-PET studies
Positron emission tomography (PET) using 2-[18F]fluoro-2-
deoxy-D-glucose (FDG) has become an important tool for
diagnosis, staging, prognosis and treatment-response moni-
toring in oncology [1]. Vansteenkiste and Stroobants [2] re-
viewed the role of FDG-PET in respiratory oncology. In their
paper, the authors addresses various aspects of FDG-PET in
oncology and discuss amongst others that improved medi-
astinal lymph node staging of patients is obtained using PET
compared with computed tomography(CT) alone. De Geus-
Oei et al. [3] performed a systematic review on the predictive
and prognostic value of FDG-PET in non-small cell lung
cancer and concluded that the degree of FDG uptake is of
prognostic value at initial presentation, after induction treatment
before resection, and in case of recurrence. Weber et al. [4]
studied the use of PET for monitoring cancer therapy and for
predicting outcome. In his paper, the author addresses many
issues involved in quantitative assessment of therapy-induced
changes in FDG tumour uptake. To date, there are numerous
papers on the promising role of FDG-PET in oncology [5–9].
While the important potential of FDG-PET in oncology has
been demonstrated in many investigations and papers, many
of these studies discuss the need for standardisation, especial-
ly for multi-centre trials and for meta-analyses. Standardisa-
tion becomes especially important when quantification of
FDG-PET studies using standardised uptake values (SUV) is
performed [10–12]. Although visual inspection of FDG-PET
images remains very important for diagnosis and response
assessment, it has been shown that semiquantitative analysis
(SUV) allows an objective assessment for lesion character-
isation [13], prognostic stratification [3] and monitoring
treatment response [14]. The latter is generally measured by
the relative change of SUV during treatment. At the same
time, comparison of SUV results obtained from different
centres is hampered by the disperse variability in methodol-
ogy of acquisition, image reconstruction and data analysis
procedures applied. Boellaard et al. [10] showed that many
technical factors, such as image reconstruction settings and
region of interest strategies, can have a major impact on the
outcome of SUV. Jaskowiak et al. [15] showed the impact of
OSEM reconstruction settings on SUV. Stahl et al. [16] and
Krak et al. [17] evaluated the effects of various clinical and
technical factors on test–retest variability and absolute out-
come of SUVand the impact of using various SUV measures
on observed treatment response. Recently, Westerterp et al.
[12] evaluated quantification of FDG-PET studies in multi-
centre trials with a focus on methodological variability among
centres. These and other studies showed the need for har-
monisation of FDG-PET across centres.
The need for standardisation was already addressed in
1999 by a position paper of Young et al. [18]. In that paper,
various methods for quantification of FDG-PET studies,
such as visual inspection, use of SUVor full kinetic analysis,
were discussed. In addition, factors affecting FDG uptake are
described. Taking into account these factors, a set of recom-
mendations was presented. More recently, in 2006, Shankar
et al. [19] published the concensus recommendations for
FDG-PET studies as indicator of therapeutic response in
patients in National Cancer Institute Trials. The guidelines
given in the latter paper focus on patient preparation, image
acquisition, image reconstruction, quantitative and semi-
quantitative image analysis, quality assurance, reproducibil-
ity and other factors in FDG-PET studies before and after a
therapeutic intervention. Larson and Schwartz [20] stated
that these NCI guidelines provide an excellent starting point
for standardisation of the use of FDG-PET in clinical trials.
Other authors, such as Zijlstra et al. [21] and Juweid et al.
[22], stressed on the need for harmonisation of interpretation
of FDG-PET studies in lymphoma either using visual ins-
pection and/or using relative changes in SUV. More guide-
lines are being developed as technology moves forward [23].
Recently, Delbeke et al. [24] therefore provided procedure
guidelines for tumour imaging with FDG PET-CT.
Although many issues are addressed in the aforementioned
papers, there is still a need for standardisation of FDG-PET
studies in case of multi-centre studies focussing on quantifi-
cation using SUV. Therefore, a PET imaging working group
was formed by the Dutch Society of Haemato-Oncology
(HOVON, Hemato-Oncologie Vereniging voor Volwassenen
in Nederland) and by Nuclear Medicine Physicians, repre-
sentatives of the Dutch Society of Nuclear Medicine, and
Medical Physicists, representatives of the Dutch Society of
Nuclear Medicine and Dutch Society of Clinical Physics, with
the task of formulating a protocol for standardisation and
quantification of FDG Whole Body PET studies in multi-
centre trials in The Netherlands. The protocol specifically
aims at standardisation of FDG-PET studies in order to allow
inter-institute interchangeability of SUV. The first version of
the protocol was finalized in November 2007 and was ap-
proved by the Dutch Society of Nuclear Medicine. The
purpose of the present paper is to provide a description of the
protocol and the rationale for recommendations given. First,
factors affecting SUVoutcome will be summarized shortly as
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these have been addressed extensively elsewhere. Next, guide-
lines and recommendations will be described in the main part
of the paper. Finally, limitations, pending issues and future
work will be addressed.
A brief summary of factors affecting SUV
Various factors and sources of error affect SUV outcome.
These factors can be assigned to physiological effects, sources
of error and physical effects.
Physiological factors affecting SUV are, for example, the
plasma glucose level during FDG-PETscanning, FDG plasma
clearance during the phase of FDG uptake, the scanning
period and the effects of patient motion and breathing. As
FDG uptake is time dependent, the time interval applied
between FDG administration and execution of the PET study
will affect SUV as well. For response monitoring, the time
interval between the baseline FDG-PET study and start of
treatment as well as the time intervals between subsequent
FDG-PET studies and cycles of treatment are of importance.
This is especially important when inflammatory processes
may occur as may be the case during or after radiation therapy.
These factors and their impact on SUV outcome are
summarized in Table 1.
Table 2 presents some of the most common errors affecting
SUV, as also described by Weber et al. [4] and Shankar et al.
[19]. Correct calculation of SUV depends on an accurate
(cross-)calibration between PET or PET-CT scanner and the
dose calibrator used for measuring patient dose. Moreover,
the net dose given to the patient needs to be known exactly.
Thus, any remaining activity in the syringe after administra-
tion should be minimized to within 1% using appropriate
procedures. Alternatively, remaining activity in the syringe
may be measured after the administration. In the majority
(95%) of the cases, remaining activity in the syringe is
smaller than 3% of the specified dose, although occasionally
(5% of the cases) remaining activity was more than 10%
(unpublished data), which mainly occurred when specific acti-
vities are still high (i.e., shortly after production). The effects of
dead volume in the syringe preparation system and adminis-
tration system should thus be carefully taken into account. A
subtractionmethod to derive the amount of activity in a syringe
may be used. The latter is generally based on subtracting a
small amount of FDG from a stock, positioned in a dose
calibrator, and measuring the amount of activity of the stock
prior and after withdrawal of the patient dose. If the stock
contains a large amount of activity relative to that needed for
the patient dose, care has to be taken that dead volume or
statistical errors do not affect accuracy and reproducibility of
net dose assessment. With proper procedures, however, this
can be handled easily. A frequently overlooked problem may
arise from an incorrect synchronisation of clocks in a PET
system with those of the dose calibrator used (or computer
attached to it for read-out and/or) or with clocks in various
rooms/locations.Moreover, as the patient dose is specified at
a certain dose calibration time, which is generally not
exactly equal to the actual injection time, correct decay
corrections have to be applied. This means that decay
between calibration time and PET acquisition time needs to
be applied to the dose specified at the dose calibration time.
Obviously, paravenous injection may still allow visual
interpretation of the PET study, but will make quantification
based on SUV incorrect. A reproducible and correct
administration of FDG is required.
Physical or technical factors affecting SUV outcome
(Table 3) are described in various papers. Data acquisition
settings such as time per bed position, the amount of overlap
between subsequent bed positions, acquisition mode (2D or
3D) and FDG dose affect scan statistics and/or the noise
equivalent count level of PET studies. Poorer scan statistics
and lower image signal-to-noise ratio (SNR) will result in an
upward bias of SUV, especially when using the maximum
SUV as final outcome parameter [10].
Nowadays, attenuation corrections will be mostly derived
from a dedicated CT scan (CT-AC) acquired on a PET-CT
scanner. Patient motion (e.g., breathing) may result in a mis-
match between PET and CT and thus result in incorrect atten-
uation correction. The latter may be minimized by breathing
instructions (breath holding at mid-inspiration volume or
shallow breathing) during CT scanning. Use of respiratory
gating would be beneficial, but is not yet routinely available in
most centres. Use of contrast agents may affect accuracy of
conversion of CT-AC image Hounsfield units into 511 keV
Table 1 Biological factor affecting SUV outcome
Biological factor Effect
Blood glucose level Lower uptake or SUV with increasing
blood glucose level
Uptake period Higher SUV at increasing time
interval between injection and start
of PET study
Patient motion/breathing Image artefacts in case of mismatch in
position between CT-AC and emission
scan and (possibly) lower SUV due to
respiratory motion (resolution loss)
Patient comfort Patient stress and uncomfortable waiting
conditions increase uptake of FDG in
muscle and/or brown fat and may affect
SUV quantification, also in case of low
tumour-to-background ratios due to
spillover.
Inflammation Inflammatory processes near or at the
tumour results in a false positive
increase of SUV.
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linear attenuation correction factors and thereby accuracy of
SUV. Hopefully, sophisticated algorithms to perform this
conversion will be introduced allowing for use of contrast
agents, as will be discussed in more detail later. Finally, atten-
uation correction based on CTcould be affected by truncation
of the CT image. Note that CT truncation does not only affect
the quantification of PET at the position of CT image trun-
cation alone, but may affect SUV of tumours located else-
where in the same axial planes as well.
Image reconstruction methods and settings determine both
quantitative accuracy and final image resolution. With itera-
tive reconstruction methods, a sufficient amount of iterations
(or the product of the number of iterations and subsets) need to
be applied to ensure sufficient convergence of the algorithm.
Insufficient convergence will result in an object- (and/or
surroundings) dependent SUV outcome [15]. In addition to
these settings, generally some filtering is performed during
or post-reconstruction. Typically, Gaussian filters of 5 to
10 mm full width at half maximum (FWHM) are applied
resulting in a clinical image resolution of 7 to 12 mm FWHM.
Image matrix size and zoom factors applied during recon-
struction determine the final voxel size and may lead to
additional image resolution loss when voxel size is larger than
half the intended FWHM (Nyquist criteria). The final image
resolution has a large effect on so-called partial volume effects
(PVE), which results in an underestimation of SUV for small
objects. PVE increases with decreasing image resolution.
PVE becomes mainly important for lesions smaller than three
times the FWHM. To date, no accurate and precise PVE
correction are available for objects smaller than about two
times the FWHM (i.e., generally <15 to 20 mm diameter).
Consequently, image resolution must be matched as closely as
possible among centres in multi-centre trials to avoid differ-
ences in SUV due to difference in image resolution. Other
data acquisition setting and reconstruction parameters, such as
the use of time of flight and relaxation parameters, affect
image quality and SUV outcome. When images have been
collected, additional variability in SUV results from different
data analysis strategies, especially region of interest (ROI)
definitions. Fixed size ROI providing ‘SUV peak’, maximum
pixel values providing ‘SUVmax’ or the average ROI value
within a 2D or 3DROI providing ‘SUVmean’ are being used.
Moreover, 2D and 3D ROI can be generated manually or
using various semiautomatic procedures, the latter generally
based on some percentage threshold value relative to maxi-
mum SUV. Examples of the effects of the number of OSEM
iterations and different image resolutions using various ROI
on SUV are shown in Fig. 1. Finally, various SUV normal-
isations are being utilized such as SUV normalised by body
weight, body surface area or lean body mass.
Table 3 Technical factors affecting SUV
Factor Effect
Scan acquisition parameters (acquisition mode, scan
duration, bed overlap, FDG dose)
Affect signal to noise ratio (SNR) of PET scan. Poorer SNR results in an upward bias of
SUV.
Image reconstruction settings (number of iterations,
filters, matrix size, zoom factors)
Affect convergence of iterative reconstructions and final spatial resolution (filter, matrix,
zoom) of reconstructed image. Insufficient convergence and lower resolution results in
lower SUV and increases partial volume effects. Moreover, insufficient convergence
makes SUV more dependent on surrounding activity distributions.
Region of interest (ROI) strategy to derive SUV Higher or lower SUV depending on size and type of ROI used.
Normalisation factor in SUV calculation SUV outcomes are numerically different when using body weight, body surface area or
lean body mass as normalisation factor in the SUV equation
Correction for blood glucose level in SUV calculation Higher blood glucose levels will result in underestimation of SUV. Use of a blood
glucose level correction in the SUV equation will thus result in different SUV outcomes.
Use of contrast agents during CT-AC Can result in overestimation of attenuation and thus results in higher SUV (upward bias).
Table 2 Errors affecting SUV
Error Effect
Cross-calibration between PET and dose calibrator (DC) Systematic error in SUV equal to error in (relative) cross-calibration
between PET and DC
Residual activities in administration system (syringe, lines etc.) Lower net administered dose resulting in incorrect lower uptake and SUV
Incorrect synchronisation of clocks of PET camera and DC Incorrect decay correction resulting in incorrect SUV
Use of injection time rather than dose calibration time (or use of
incorrect amount of dose)
Incorrect time interval is used for decay correction of administered dose
resulting in incorrect SUV
Paravenous administration of FDG Paravenous injection results in slow delivery of FDG to the tumour and
therefore in incorrect SUV
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A standardised protocol for FDG-PET
whole body studies
The protocol for standardisation and quantification of FDG-
PETwhole body studies is based on principles for minimizing
intersubject and inter-institute variability of SUV measures:
& Recommendations for patient preparation are specified
in order to minimize patient related or other physiolog-
ical effects on SUV accuracy and reproducibility. More-
over, guidelines aim at optimizing FDG uptake in the
tumour, minimizing uptake in surrounding tissues (mus-
cle, brown fat) and minimizing SUV variability.
& Recommendations for the administration procedure are
given to ensure that the net dose given to the patient is
exactly known by avoiding (unknown) remaining activ-
ities during preparation and administration.
& FDG dose is specified as a function of patient weight,
scanning mode, percentage bed overlap, and acquisition
time per bed position. In this way, it is attempted to obtain
a smaller range in scan statistics between subjects, because
of a difference in weight, and between different scanners,
due to difference in sensitivity and applied overlap of
subsequent scan bed positions.
& Interchangeability of SUV (or it’s absence) is, to a large
extent, affected by the overall spatial resolution of the PET
images after reconstruction, filtering or smoothing and
processing.Resolution matching across scanners or centres
is therefore needed to allow for SUV interchangeability.
& After PET acquisition and image reconstruction, SUVout-
come is determined by data analysis procedures. Common
region of interest (ROI) strategies are the use of fixed
sized 2D or 3D ROI, manually defined ROI in one or more
axial slices and 3D ROI based on region growing
procedures while applying a user-specified threshold.
Preferred and obligatory ROI therefore need to be specified.
& Various SUV normalisations can be applied such as body
weight, body surface area and lean body mass. More-
over, SUV may be corrected for blood glucose level. In
order to interpret reported SUV it is mandatory to clearly
indicate and specify which SUV measure will be used.
& Finally, it is essential that (1) the PET scanner is technically
operating according to specifications, that (2) the PETscan-
ner and the dose calibrator used to determine patient FDG
dose are calibrated against each other correctly, including
synchronisation of clocks used within the department, and
that (3) performance of PET scanner and the characteristics
of reconstructed PET studies, such as SNR, uniformity and
spatial resolution (specified in terms of activity recovery
coefficients) remain consistent or are known after hardware,
firmware and software upgrades. To this end, multicentre
QC measures are therefore specified.
Patient preparation
1. Patients should have fasted for at least 4 h and preferably
6 h before administration of FDG.
2. Ample hydration is recommended by intake of 1 l of
water during 2 h prior to administration of FDG. In case
of venous hydration, no glucose may be present in the
infusate.
3. After administration of FDG, patients should drink
0.5 l water before the PETexamination.When necessary,
0.5 l water or saline can be given intraveneously.
SUV max = 4.0 5.9 6.4 8.6
SUV 50% = 3.0 4.1 4.6 5.9
(A) (B) (C) (D) 
Fig. 1 Images illustrating effects of the number of OSEM iterations
and image smoothing on SUV. Representative image reconstruction
settings, as observed in a previous multicentre study, were taken.
Images were reconstructed using OSEM with two iterations, eight
subsets and smoothed using a 8-mm FWHM Gaussian filter (a, c) and
using OSEM with four iterations, 16 subsets and smoothed with a 5-
mm FWHM Gaussian filter (b, d)
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4. No or minimal exercise 4 h prior to and after FDG
administration and during the entire PET examination.
However, patients are allowed to visit the rest room.
Instruction should be given to the patients to relax,
avoid motion and unnecessary talking.
5. Patients are asked to void the bladder shortly (5 to
10 min) before the PET examination.
6. Blood glucose level must be measured before admin-
istration of FDG. If blood glucose level is greater than
11 mmol/l, the patient must be rescheduled. In case
blood glucose level is being used to correct SUV, it
must be measured at the clinical laboratory of the hos-
pital using valid methodology.
7. Waiting conditions, preparation room and room temper-
ature must be comfortable to allow optimal resting con-
ditions during and after FDG administration in order to
minimize muscle and brown-fat uptake. Blankets must
be provided to the patient when needed/requested.
8. An urinary catheter may be used upon indication,
preferably placed before administration of FDG.
9. Administration of a diuretic may be considered in case
of expected pathology in the lower abdomen.
10. Routine use of tranquilizers (benzodiazepines) is not
recommended, but may be considered in case tumours
are expected in the head and neck region to minimize
FDG muscle uptake. Benzodiazepines have no further
use for suppressing the so-called brown fat phenomenon.
11. Patient weight and height must be measured using
calibrated and medically approved devices.
12. Date of last cycle of chemotherapy, administration of
growth factors (G-CSF, GM-CSF) or other treatments must
be reported. Intervals between interventions and PET
should be specified for each (research) protocol. For
routine clinical care in solid tumours, an interval between
end of last (chemo-)therapy cycle and FDG-PETmust be at
least 14 days. In case of radiation treatment, an interval up
to 4 months may be required occasionally (e.g., larynx
carcinoma). For malignant lymphoma therapy evaluation,
time intervals have been specified by the Imaging
Subcommittee of International Harmonization Project in
Lymphoma [22].
In case of type II diabetes mellitus, the following additional
guidelines apply:
1. Study will be scheduled preferably at the end of morning
2. Patients will need to be fasted for at least 4 h. Intake of
water is recommended as is nondiabetics.
3. Oral antidiabetic drugs should be continued.
In case of type I and insulin-dependent type II diabetes
mellitus, the following additional guidelines apply:
1. It is preferred to reach normal blood glucose levels in
mutual agreement with patient and referring physician
2. Study will be scheduled preferably at the end of morning
3. Patient will have a normal breakfast at 7:00 A.M. and
uses a regular dose of insulin, followed by fasting as
described above.
FDG administration procedure
The procedure aims at an accurate and reproducible adminis-
tration of FDG, minimizing or avoiding remaining activity in
the administration system and thus ensuring that the exact net
dose administered is known. This is a prerequisite for accurate
SUV calculations as discussed previously in the “A brief
summary of factors affecting SUV” section because the net
dose administered to the patient is used directly in the SUV
equation (Eqs. 1 and 2).
It is preferred to administer FDG through a three-way
valve system attached to a venous canula. After injection,
the entire administration system should be flushed with at
least 10 cc saline to avoid remaining activity in the system.
One should be aware of any activity remaining in the
syringe, needle or administration system. If rest–activity in
syringe, needle or administration system cannot be mini-
mized using appropriate procedures (<1%); remaining
activity should be measured afterwards in a calibrated dose
calibrator.
FDG dosage in relation to scanner type, patient weight
and time per bed position
A prescription of FDG dosage as function of patient weight,
scanner type, percentage bed overlap, and time per bed po-
sition is given to minimize variability in scan statistics across
scanners and patients (with different weights). As an upward
bias (maximum), SUV was seen with decreasing image SNR
minimizing (referentie?), scan statistics variability across
centres, and patients will thus improve interchangeability of
SUV in multi-centre studies.
In principle, a dosage of 5 MBq/kg for 2D scanners and
2.5 MB/kg for 3D scanners with minimal bed overlap
(<25%) assuming a (fixed) 5 min emission scan per bed
position is used. In case of 3D scanners with a 50% bed
overlap of subsequent bed positions of a whole body PET
scan 1.25 MBq/kg is sufficient. For shorter scan times per
bed position, the dosage can be adjusted proportionally but
with an additional surplus of 10% to (partly) compensate for
lower noise equivalent count rates per MBq at higher doses.
The following formulas apply to determine the patient
specific FDG dosage (MBq):
1. For 2D PET scanners with less than 25% bed overlap
the total amount of FDG dose is given by:
a. Dosage=27.5 times patient weight (kg) and divided
by the scan time per bed position (min per bed)
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2. For 3D PET scanners with less than 25% bed overlap
the total amount of FDG dose is given by:
a. Dosage=13.8 times patient weight (kg) and divided
by the scan time per bed position (min per bed)
3. For 3D PET scanners with 50% bed overlap the total
amount of FDG dose is given by:
a. Dosage=6.9 times patient weight (kg) and divided by
the scan time per bed position (min per bed)
The following additional recommendations apply:
1. Net administered dose should be within 10% of the re-
commended dose but must be exactly known within
3%.
2. Increasing the FDG dosage to reduce overall scanning
time should not result in count rates exceeding the maxi-
mum count rate capabilities of the PET scanner, i.e.,
above which corrections for dead time or others can no
longer be accurately performed (<5%). When specified,
the recommendations of the manufacturer on maximum
dosage should be followed.
3. When variable scan times per bed position can be
applied, it is allowed to reduce the scan time per bed
position with 50% for scan trajectories outside thorax
and abdomen (thus for head, neck and legs) to
reduce overall scanning time. For the calculation of
the FDG dose, it is still required to use the scan time
per bed as needed for scans at the thorax and
abdomen regions.
4. To facilitate clinical use, a table specifying required
FDG dose in 10 kg patient weight steps may be
used. An example of such a table is given in
Table 4.
Exceptions
For new scanners, e.g., scanners with time of flight (ToF) or
equipped with new reconstruction methods (e.g., recovery
correction), it is allowed to deviate from the above specifica-
tions. In the latter case, it is up to the users to demonstrate that
use of other than the recommended dose-scan time per bed
specifications does not result in a change of observed SUV. To
that end, the deviation from the above-given specifications
must be justified using phantom experiments, as described
later in the QC section of this protocol, as well as by a clinical
study relevant to the ongoing multi-centre study (i.e., using the
same patient population). In this way, this protocol facilitates a
proper validation of new technology for quantitative FDG-
PET studies and ensures exchange of SUV in multi-centre
studies while allowing benefits of new technology.
PET and PET-CT acquisitions
1. Emission scanning should start at 55 to 65 min after
FDG administration
2. For most oncological applications, a ‘whole body’ scan
trajectory extends from proximal thigh up to skull-base.
Scanning direction should be in the caudocranial direction
to have minimal bladder filling at the time of scanning the
lower abdomen (‘feet first’). Alternative scan trajectories
can be used upon indication.
3. During PET-CT, arms should preferably be elevated over
the head to minimize streak artefacts (in case of posi-
tioning along the body) due to, e.g., beam hardening of
CT-AC.
4. Correct isotope and decay times should be set or entered
in the acquisition computer.
Table 4 FDG dose as function of patient weight (10 kg steps)
Mode 2D 3D 3D 3D 3D 3D 3D 3D 3D
Time/bed 5 5 4 3 2 5 4 3 2
Bed overlap (%) 25 25 25 25 25 50 50 50 50
Patient weight (kg) FDG Dose (MBq)
30–39 170 80 120 160 240 40 60 80 120
40–49 220 110 150 200 310 60 70 100 150
50–59 270 130 180 250 370 70 90 120 180
60–69 320 160 220 290 440 80 110 140 220
70–79 370 180 250 340 510 100 120 170 250
80–89 420 210 290 390 580 110 140 190 290
90–99 470 230 320 430 650 130 160 210 320
100–109 520 260 360 480 720 140 180 240 360
110–119 570 280 390 520 – 150 190 260 390
120–129 620 310 430 570 – 170 210 280 430
130–139 670 330 460 620 – 180 230 310 460
140–149 720 360 500 660 – 200 250 330 500
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5. FDG dosage, dose calibration time, patient weight must
be correctly set when required by the acquisition
software.
6. Online random correction based on delayed coinci-
dence window technique is recommended.
7. For CT-based attenuation correction generally a low-dose
CT is performed (CT-AC). For the CT-AC scan, the re-
commendations provided by the manufacturer may be
followed. Generally, CT-AC scans are operated using
30 mAs or less. During and prior to CT-AC scanning, no
intravenous contrast agents may be used (until it has been
unequivocally demonstrated that this does not affect
SUV).
8. During CT-AC, shallow breathing is recommended for
multi-slice CT scanners to minimize effects of patient
motion on attenuation correction.
9. General PET-CT procedure consists of a scout scan
for positioning the PET and CT scan trajectories.
Next, a low-dose CT scan for attenuation correction is
performed followed by the emission scan. Upon
indication, the procedure may be concluded by a
diagnostic CT scan including use of intravenous
contrast agents and applying maximal inspiration
breath hold. Diagnostic CT settings should be accord-
ing to specifications provided by the radiologist and/
or specialised medical physicist.
Pitfalls and additional recommendations:
1. For certain PET-CTscanners, the CTor CT-AC FOVmay
be smaller than that of the PET. Therefore, truncation of
CT-AC should be avoided to avoid attenuation (and
scatter) correction artefacts and quantification errors.
2. In case transmission scans based on radioactive sources
(generally Ge-68 line sources) are used for attenuation
correction, these sources must have sufficient strength
to acquire transmission scans. Low transmission source
activity will result in poor SNR in transmission scans
affecting image quality and quantification of emission
scans. Transmission scan sources should fulfill criteria
specified by the manufacturer. Moreover, Ge-68 line
sources need to be replaced at least every 1.5 years.
PET image reconstruction
Based on a phantom study (Fig. 2), it was observed that most
modern PET-CT scanners provide images with a spatial re-
solution close to 7 mm FWHM when using the default by
the manufacturer-recommended image reconstruction set-
tings. It is therefore attempted that PET studies from various
scanners and centres will have a final image resolution as
close as possible to 7 mm FWHM. When possible, specific
image reconstruction algorithms and settings are defined per
scanner. Settings are chosen such that, for iterative recon-
structions, sufficient convergence is achieved. Other settings,
such as smoothing filters and image matrix size, will be
chosen such that final image resolution will be close to
7 mm FWHM. Optimal settings need to be derived so that
activity concentration recovery coefficients as function of
sphere size will meet QC specifications, as described later
(Fig. 2). The latter procedure is followed, as use of point
sources for verification of image resolution should not be
used in case of iterative reconstruction methods, which are
exclusively used nowadays for FDG-PETwhole body studies.
Moreover, variably sized spheres, simulating tumours, resem-
ble clinical conditions more closely than point sources. The
phantom experiments, as part of multicentre QC procedures,
will be described later.
The following reconstruction parameters are defined.
1. All correction methods needed for quantification need
to be applied. These include decay correction, dead time
correction, corrections for detector efficiencies (nor-
malisation), random correction, attenuation correction
and model-based scatter correction, such as the single
scatter simulation method by Watson et al. [25] or
similar ones
2. Additional and indicative reconstruction settings are
suggested.
For Siemens/CTI scanners:
& (FORE+) 2D OSEM reconstruction with four iterations
and 16 subsets.







































Fig. 2 Average (±1 SD) activity
concentration recovery coeffi-
cients as function of sphere size
observed with image quality
control measurements at eight
different scanners using a an
adaptive 50% isocountour VOI
(A50%) and b maximum pixel
value
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& Model-based scatter correction.
& Matrix size of 128×128
& Zoom=1.0
For GE scanners:
& Default reconstruction settings (generally OSEM with
about two iterations and 30 subsets for 2D scans and
FORE+2D OSEM with five iterations and 21 subsets for
3D scans)
& A post-reconstruction smoothing using a 5-mm FWHM
Gaussian filter
& Model-based scatter correction
& Matrix size of 128×128
& Zoom=1.0
For Philips scanners:
& For scanners equipped with time of flight (ToF), the
default reconstruction methods (LOR based reconstruc-
tion including ToF) should be used applying ‘normal’
smoothing setting
& For scanners without ToF, reconstructions should be
performed using LOR-RAMLA or 3D RAMLA apply-
ing four iterations and other settings as specified by the
manufacturer.
& Matrix size of 144×144 (default)
& Zoom=1.0
3. Exceptions and additional remarks
As technology moves forward and new scanners and/or
new reconstruction algorithms are being developed, the afore-
mentioned scanner-specific recommendations may become
obsolete. Consequently, it is allowed to deviate from the re-
commended reconstruction parameters provided that recon-
structed images still meet the quality control criteria,
especially those for activity concentration recovery coeffi-
cients measured in the NEMA NU 2 2001 Image Quality
phantom, as specified later in the QC section.
Scanners which are not equipped with accurate random
correction (based on singles or delayed coincidence time
window technique) or with model-based scatter correction
cannot be used when absolute SUV quantification is need-
ed. However, these scanners may still be used in studies in
which relative SUV changes are used to assess treatment
response provided that the patient is scanned in an identical
manner on the same scanner and using the same recon-
struction settings and analysis methods during all subse-
quent scans.
Data analysis—volume of interest definitions
Beyond acquisition and image reconstruction, the SUV result
is determined by data analysis procedures. Common region or
volume of interest (ROI, VOI) strategies are the use of fixed-
sized 2D or 3D ROI, manually defined ROI in one or more
axial slices and 3D ROI based on region-growing procedures
while applying a user-specified threshold. In order to ex-
change SUVacross centres, referred and obligatory ROI need
to be specified.
The following regions of interest are suggested to be useful
& 3D isocount contour at 41% of maximum uptake in-
cluding local background corrections, i.e., an adaptive
41% VOI (VOIA41) [10, 26].
& 3D isocount contour at 50% of maximum uptake (VOI50)
& 3D isocount contour at 50% of maximum uptake in-
cluding local background corrections (VOIA50)[10, 17].
& 3D isocount contour at 70% of maximum uptake
(VOI70).
& 3D isocount contour at 70% of maximum uptake in-
cluding local background corrections (VOIA70) [10, 17].
& Maximum voxel value (Max)
Use of VOIA41 is based on results of recovery
coefficient phantom experiments, such as the one de-
scribed in the QC section later on, in which it can
observed that using an adaptive 41% threshold provides
VOI with a volume close to real sphere volumes used.
Moreover, this or a similar threshold VOI has been
suggested for radiation oncology purposes [26–29], al-
though many other VOI strategies have been suggested for
the latter purpose as well [30, 31].
Use of VOI50, VOIA50,VOI70, VOIA70 are commonly ap-
plied VOI and are included to allow comparison of SUV
with those reported in previous studies. The maximum pixel
value is nowadays most frequently used, and it is especially
attractive as it does not require specialized algorithms to
automatically generate VOI, and it does not suffer from
observer variability as may be seen when using manually
defined VOI.
VOI recommendations:
1. The maximum voxel value or maximum SUV (SUVmax)
must always be reported.
2. Use of larger VOI may provide SUVestimates with better
precision (smaller uncertainty). Therefore, in a response
monitoring settings, use of VOIA41 should be attempted
in all sequential scans of a patient. When VOIA41 does
not provide meaningful tumour definitions, as needs to
be checked visually, smaller VOI obtained with higher
percentage threshold values can be applied [10, 12, 17].
Subsequently and in this order, VOI50, VOIA50,VOI70,
VOIA70 may then be used consistently in all scans of a
subject. However, when it is expected that one or more
of these VOI may not be useful for certain studies, it is
optional to agree upon the use of VOI70 and the maxi-
mum uptake beforehand. In all cases, SUVmax and its
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change need to be reported in addition to all other VOI
strategies agreed upon.
3. Automatic procedures for generating 3D isocount con-
tours may fail in case of low tumour-to-background ratios
or in the vicinity of organs showing high uptake (bladder,
heart, brain). It is recommended to visually check if the
automatically generated volume of interest corresponds
with the localisation of the lesion, i.e., without inclusion
of non-tumour structures or organs. In case automated
VOI strategies cannot be applied reliably, the maximum
SUV should be derived from a manually drawn 3D
volume of interest which includes the entire tumour and
excludes normal tissue.
Data analysis—scan report and SUV calculation
1. PETand PET-CT scans will be evaluated visually directly
from a computer screen by a trained Nuclear Medicine
Physician. Attention will be paid to the presence or
absence of abnormal focal FDG avidities as well as their
size and uptake. Both images reconstructed with and
without attenuation correction need to be evaluated to rule
out artefacts due to patient motion, metal implants, or
contrast agents. Findings need to be reported and corre-
lated to those seen with other diagnostic modalities or
findings (if any).
2. It is recommended to report SUV normalised by body
weight. However, besides weight, also patient height
and gender should be reported thereby allowing
calculating other SUV measures. Use of blood glucose
level correction is not mandatory, but may be per-
formed in addition to non-blood glucose level corrected
SUV measures. SUV normalised by body weight
without or with blood glucose level correction are cal-
culated as follows:
SUV ¼ ACvoi kBq=mlð Þ
FDGdose( MBq )=BW(kg)
ð1Þ
SUVglu ¼ ACvoi kBq=mlð Þ
FDGdose( MBq )=BW kgð Þ
 Pglu mmol=lð Þ
5:0
ð2Þ
In Eqs. 1 and 2, ACvoi represent the average activity
concentration in kBq/ml in the specified volume of interest
(or the maximum value). FDGdose is the administered dose
of FDG in MBq and BW is the body weight in kg. Pglu
represent blood glucose level in mmol/l. In case SUV is
corrected for blood glucose level, i.e., SUVglu, the observed
Pglu is normalised by 5.0 representing approximately the
population average Pglu value.
Data exchange
When data (FDG-PET images) need to be exchanged within a
multi-centre study, it is required to specify image data format
and meta-data required for accurate SUV calculations.
DICOM images may be stored in various units, such as
‘counts’, ‘SUV’ or “Bq/cc”. Therefore, when using DICOM
format, one has to verify that all factors (scaling and cali-
bration factors) are present in the header of the DICOM files
in order to allow quantification of the images.
The following (minimal) recommendations are specified:
DICOM format should meet the specifications “Digital
Imaging and Communications in Medicine (DICOM),
Part 10: Media Storage and File Format for Media
Interchange “given by National Electrical Manufac-
turers Association (NEMA; http://dicom.nema.org/)
In addition, DICOM format should meet the Confor-
mance Statement written by the manufacturer of the
PET or PET-CT scanner.
All data, including DICOM images, need to be anony-
mised. Patient name and ID need to be erased or replace
by study ID and randomisation number, respectively,
before sending these data to other centres. The birth date
needs to be erased as well. This is especially required
when data are exchanged over the Internet.
DICOM images or headers have to contain all factors
(scaling and calibration factors) required for quantifi-
cation of the images.
Transport of data or DICOM images may be performed
by storing it on media (CD or DVD) and sending it by
regular mail to other centres. However, electronic tran-
sport using ftp is allowed provided that ftp is secured and
ftp-server password protected.Moreover, all (image) data
need to be anonymised.
All additional information needed to calculate SUV
must be provided. This information, such as study ID,
patient randomnisation number, patient weight, height,
gender, administered dose, dose calibration time,
injection time may be entered during acquisition so
that these information will be present in the header of
the DICOM image. It is, however, strongly recom-
mended to exchange an additional digital scan report
form providing all required data, as frequently essential
information is still missing. The scan report form should
contain study ID, patient randomnisation number, length,
weight, gender, administered dose, dose calibration time,
injection time, PET scan start time, scan duration,
hospital and department, responsible physician and/or
address for correspondence.
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Multi-centre QC measures
In order to achieve interchangeability of SUV, a set of PET or
PET-CT scanner quality control procedures is required. In
case of PET-CTscanners, it is recommended to perform all CT
QC measures as recommended and implemented by the
manufacturer. Furthermore, other guidelines for execution of
diagnostic CT studies and of CT-QC measures on a PET-CT
scanner should follow the recommendations provided by the
Radiological Society and/or upon indication by a radiologist.
In addition, correct alignment between PETand CT data must
be checked following manufacturer supplied procedures.
In the remainder of this paper, recommendations focus on
PET QC measures specific for accurate SUV measurements.
The following PET QC measures are recommended: (1) daily
quality control; (2) (cross-)calibration of PET or PET-CT
scanner against the (local) dose calibrator used for measure-
ment of patient-specific FDG doses and; (3) an inter-institute
cross-calibration and recovery coefficient assessment.
1. Daily quality control (DailyQC)
The purpose of a DailyQC is to assess correct functioning
of the PET or PET-CT system, i.e., to detect detector failures
and/or (overall) drift. Most commercial PET and PET-CT
systems are equipped with a (semi-) automatic procedure for
performing a DailyQC. It is recommended to follow the pro-
cedure provided by the manufacturer. The user has to check
whether the DailyQC has passed the test correctly.
2. Quality control of (Cross-)Calibration of PET or PET-
CT system
The purpose of the (cross-)calibration is to assure correct
and direct calibration of the PET or PET-CT camera against
the (local) dose calibrator used for measurement of the (FDG)
dose to be administered to the patient [32]. In case patient-
specific doses are directly ordered from or provided by a
pharmaceutical company, the cross-calibration of the PET or
PET-CT has to be performed based on a calibrated FDG
sample provided by that company. Note that the cross-
calibration is the direct relative calibration of the PET system
against the (locally) used dose calibrator, and it therefore
provides information about potential discrepancies in cali-
bration between PET and dose calibrator. The latter is
required because separate calibration of dose calibrators,
well counters and PET-CT systems may still result in (small)
discrepancies under specific clinical conditions. Standard
operating procedures (SOP) for performing the PET (cross)
calibration QC are made and provided to all Dutch centres.
The procedure has been described elsewhere in more
detail [32]. A crucial principle of the calibration QC is
that, during execution of this measurement, acquisition
and reconstructions settings should be identical to those
used during patient studies (and as recommended in this
paper). Following the SOP, the cross-calibration factor
between the PET or PET-CT scanner and dose calibrator
should equal one within 5%.
3. Image quality and recovery coefficients
Although the aforementioned cross-calibration QC assures
correct calibration for standard conditions, SUV quantifica-
tion in multi-centre trials and inter-institute interchangeability
of SUV is still hampered by differences in applied method-
ology (e.g., due to use of different scanners, acquisition pro-
tocols, reconstruction methods and settings). For example,
differences in (reconstructed) image resolution will have a
very large effect on SUV quantification in relatively small
tumours with volumes up to 10 ml (depending on shape as
well). Therefore, it is also required to assess accuracy of SUV
using an image quality phantom containing variously sized
sphere simulating tumours. Such a phantom will allow assess-
ment of SUV accuracy in ‘tumour’-like conditions. The pur-
poses of the ‘image quality and recovery coefficients’ quality
control procedure are: (1) to assess SUV quantification in
‘tumour’ like structures; (2) to assess correct calibration/
quantification for a nonstandard phantom and; (3) to deter-
mine recovery coefficients as function of sphere (tumour)
size. The latter data can be used to compensate for differences
in image resolution and convergence properties of the avail-
able reconstruction algorithm amongst institutes and, if
needed, to adapt local acquisition and reconstruction settings
such that recovery coefficients match those specified in
Tables 5 and 6.
The ‘image quality and recovery coefficients’ quality con-
trol procedure is performed similarly to the “image quality,
accuracy of attenuation and scatter corrections” procedure of
the NEMA Standards Publication NU 2-2001 “performance
measurements of positron emission tomographs”. The main
difference is that, now, all spheres will be filled with a FDG
solution equal to about eight times the activity concentration
of the background compartment. Furthermore, acquisition,
reconstruction and data analysis (ROI) methods to measure
and determine sphere uptake are performed as recommended
in this paper for patient studies. A standard operating proce-
dure (SOP “Image Quality and recovery coefficients PET”,
Dutch version) is available in the Dutch version of the ap-
Table 5 Recovery coefficient (RC) specifications for VOIA50
Sphere volume (ml) Expected RC Maximal RC Minimal RC
26.52 0.77 0.83 0.71
11.49 0.73 0.79 0.67
5.57 0.66 0.73 0.59
2.57 0.60 0.68 0.53
1.15 0.45 0.52 0.38
0.52 0.30 0.35 0.25
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proved recommendations protocol. Following the SOP, abso-
lute activity concentration recovery coefficients as function of
sphere size are obtained. These recovery coefficients should be
within the specifications given in Tables 5 and 6 for the two
given ROI (A50% and MAX).
Limitations, observations and open issues
The recommendations in this paper aim at standardisation of
FDG-PET studies in order to achieve interchangeability of
SUV in multi-centre trials. Yet, a few issues are still open for
debate and need to be addressed in the near future. Also,
during multi-centre phantom measurements, some limitations
were encountered and will be discussed below.
First of all, the recommended FDG dose takes into account
patient weight, time per bed position, applied bed overlap and
scanning mode (2D or 3D). Although patient weight is used
directly, the variation in image quality does not depend
linearly on patient weight, and the relation between weight,
length and gender is ignored. An alternative parameter to vary
dose could be measures such as lean body mass, body surface
area or body mass index, but their relation with image quality
is not resolved as well. Secondly, it is assumed that effects of
minimal versus 50% bed overlap on image SNR equals a
factor 2. Similarly, it is also assumed that 2D and 3D ac-
quisition mode results in a factor 2 difference of SNR. Ideally,
it is optimal to assess image SNR for all scanners using
various anthropomorphic phantoms (with various sizes and
levels of outside field of view activities) to fully determine
differences in image quality amongst various scanners and use
those data to specify recommended FDG dose. The recom-
mendations given in this paper, however, offer an advantage
over the usually (fixed) dosages applied in most centres, while
they are still feasible to be used in a clinical setting. The image
quality QC experiments are used to assess any remaining
impact of image SNR on SUV quantification. So far, it has
been observed that differences between scanners and centres
are within 10% provided recommendations are followed
strictly (Fig. 2).
Occasionally, the possibility and flexibility to set acquisi-
tion and reconstruction parameters are limited. In practice,
however, it was observed that present default reconstruction
settings, as implemented by the manufacturer, closely fulfilled
the recommendations given in this paper. The limited pos-
sibilities to change or overrule the manufacturer-provided
settings is a way of standardisation by itself and may therefore
be considered as ‘beneficial’ for the moment. Yet, the impacts
of future software and hardware upgrades on SUV quantifi-
cation need to be carefully monitored. Any change in default
acquisition and reconstruction algorithm and their settings
will directly have an effect on observed SUV. Any software
and hardware upgrade should therefore be clearly specified by
the manufacturer, including a description of the effects of the
upgrade on image quality (resolution, SNR). The authors
therefore hope that PET and PET-CT scanner manufacturers
are willing to clearly specify the meaning of acquisition and
reconstruction parameters used in their software and graphical
user interface. Moreover, sufficient flexibility in changing
parameter settings would be beneficial to facilitate matching
of image SNR, convergence of iterative reconstruction methods
and image resolution in a multicentre studies.
Another observation (data not shown) is that calibration and
image quality, especially uniformity of pixel values of recon-
structed images, may differ between (same) scanners of the
same manufacturer at different sites. The consequence of this
observation is that all QC measures have to be performed at
each site to verify that the scanner characteristics and speci-
fications fulfill the criteria given in the ‘NEDPAS’ protocol.
Occasionally, we observed that cross-calibration between
PET scanner and dose calibrator revealed a (relative) dif-
ference of more than the recommended 5%. The cause of this
discrepancy is not fully understood, as the phantom used to
calibrate the scanner to the dose calibrator is or can be used to
verify correct calibration during the cross-calibration QC
measurement. One hypothesis may be that acquisition and
reconstruction settings and algorithms used during the cali-
bration procedure are not equal to those during the calibration
QC (or verification) measurements and thus not equal to that
used during patient studies. Discrepancies may also be
caused, e.g., by the use of ‘calculated’ attenuation correction
rather than using a CT-AC or a transmission scan. Other
causes might be the use of (slightly) different reconstruction
or correction algorithms or settings. Moreover, the calibration
must be performed at (a range of) count rates normally en-
countered in clinical studies. It is therefore of utmost impor-
tance that the scanner is calibrated using acquisition and
image reconstruction algorithms and settings identical to
those used during patient studies. In this way, it is assured that
results obtained during calibration are applicable to those
obtained during the calibration QC and the patient studies.
An issue to resolve is the use of contrast agents during PET-
CT studies. Several studies have been performed to assess the
effects of intravenous contrast agents on the accuracy and
image quality of PET-CT scans [33–39]. Impact of the use of
IV contrast on SUV of lesions (tumours and nodes) ranged
Table 6 Recovery coefficient (RC) specifications for ROI MAX
Sphere volume (ml) Expected RC Maximal RC Minimal RC
26.52 0.98 1.08 0.88
11.49 0.95 1.05 0.85
5.57 0.89 1.01 0.77
2.57 0.84 0.94 0.75
1.15 0.63 0.74 0.51
0.52 0.38 0.46 0.29
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from 0% to 25%. Amplitude and frequency of observed
increase in SUV depend on contrast agent used and specific
imaging protocols [40]. Moreover, effects of using intrave-
nous contrast may differ between baseline and posttreatment
scans [37]. A simple strategy to avoid any artefact or quan-
tification error is to acquire a dedicated low-dose CT-AC scan
prior to PET scanning. After concluding the entire PET
procedure, a diagnostic CT scan including use of intravenous
contrasts can then be made. Using the latter strategy, it is also
feasible to acquire the diagnostic CT at maximal inspiration to
further enhance diagnostic accuracy, while the CT-AC can be
used for localisation of FDG avid lesions.
In case of oral contrast agents, this scanning setup cannot
be followed to avoid presence of contrast agents in the patient
during CT-AC. To date, use of (diluted) oral contrast agents
during PET-CT studies is a matter of debate. Various studies
have shown that oral contrast agents affect quantification of
FDG-PET studies possibly up to 103% in the case of high
density barium contrast [41], but effects on SUV seem to be
small when using diluted or other types of contrast agents
[42–45]. The amplitude of this effect thus depends strongly
on type of contrast agent and a priori unknown local accu-
mulations. Moreover, increase of SUV seemed to be mostly
observed in the ascending colon [46]. An interesting alter-
native might be the use of negative oral contrast agents,
which do not affect the accuracy of CT-based attenuation
correction, and is therefore a promising possibility for PET-
CT studies [47, 48]. Use of negative oral contrast will
hopefully be of sufficient quality for diagnostic use, which
needs to be assessed by the radiology community.
The potential effects of contrast agents on SUV may vary
between scans and can create (extra) artificial SUV responses
in longitudinal studies. Although effects of 0% to 25% seem
small, it is just one of the many such (small) factors affecting
SUV accuracy and variability. The accumulated resulting
inaccuracy led us to argue that all (small) factors contributing
to variability in SUV across centres should be controlled as
much as possible, and this reasoning is, in fact, the main driver
of many of the presented recommendations. Based on
phantom experiments (Fig. 2), inter-institute variability due
to technical issues could be minimized to within 7% (1 SD)
provided upon strict standardisation of PET procedures. The
clinical benefit of using contrast agents should therefore be
carefully balanced against potential increased SUV variabil-
ity and/or incorrect assessments of treatment response up to
10–20% in some cases [33, 37].
Conclusions
This paper describes a protocol for standardization of quan-
titative FDG whole body multicentre PET studies. The
protocol was successfully introduced in the Netherlands
and has been approved by the Netherlands Society of
Nuclear Medicine.
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